UBD
UBD (ubiquitin like modifier D), also known as FAT10, is a ubiquitin-like protein modifier that is covalently attached to target proteins and directs them to the 26S proteasome for degradation. It is also linked to NF-kappa-B signalling, apoptosis and mitotic regulation. Browse Assay Genie's current range of UBD research reagents below, or read on for the biology behind the target.
UBD is a ubiquitin-like protein modifier. It can be covalently attached to target proteins, and this conjugation leads to their degradation by the 26S proteasome in a NUB1-dependent manner. Conjugation is activated by UBA6, which adenylates the C-terminal glycine of UBD. The protein also promotes expression of the proteasome subunit PSMB9 (LMP2).
Beyond protein turnover, UBD has been implicated in several cellular processes. It regulates TNF-induced and LPS-mediated activation of NF-kappa-B, the central mediator of innate immunity, by promoting TNF-mediated proteasomal degradation of ubiquitinated I-kappa-B-alpha. It is required for TNF-induced p65 nuclear translocation in renal tubular epithelial cells, and may be involved in dendritic cell maturation, the process by which immature dendritic cells become antigen-presenting cells that initiate T-cell responses. UBD may also contribute to the formation of aggresomes when the proteasome is saturated or impaired.
In cell division, UBD mediates mitotic non-disjunction and chromosome instability in long-term in vitro culture and in cancers. It does this by shortening mitosis and impairing kinetochore localisation of MAD2L1 during prometaphase. It also mediates caspase-dependent apoptosis, notably in renal epithelium and tubular cells in diseases such as polycystic kidney disease and HIV-associated nephropathy. The UBD gene encodes a protein with two ubiquitin-like domains and belongs to the ubiquitin D family. Upregulation may promote inflammation in chronic kidney disease and has been observed in many cancer types. The mouse and rat orthologs are both named Ubd.
UBD is conjugated to substrates and targets them to the 26S proteasome in a NUB1-dependent manner, with activation by UBA6.
UBD promotes TNF-mediated degradation of ubiquitinated I-kappa-B-alpha and regulates TNF-induced and LPS-mediated NF-kappa-B activation.
UBD impairs kinetochore localisation of MAD2L1 and mediates chromosome instability, and its upregulation has been observed in many cancer types.
UBD mediates caspase-dependent apoptosis in renal epithelium and may promote inflammation in chronic kidney disease.
UBD is a ubiquitin-like modifier that is attached covalently to target proteins and leads to their degradation by the 26S proteasome. It also regulates NF-kappa-B activation, promotes PSMB9 expression, and is implicated in apoptosis, aggresome formation, mitotic regulation and dendritic cell maturation.
Yes. FAT10 is an alias of UBD, and the previous HGNC name was simply ubiquitin D. The current approved name is ubiquitin like modifier D. Literature may use either UBD or FAT10, so it is worth searching under both names.
Mouse and rat both have an ortholog named Ubd. UBD upregulation has been observed in many cancer types and may promote inflammation in chronic kidney disease. Check the datasheet of any product for its validated reactivity.
Ubiquitin-like pathway partners, proteasome components and NF-kappa-B signalling targets related to UBD.
Gene and protein annotations from HGNC, NCBI Gene and UniProt O15205; product specifications from Assay Genie datasheets.